Rifaximin: Recent advances in gastroenterology and hepatology

Gastroenterology and Hepatology

Volumn 3, Issue 6, 2007, Pages 474-483

  Lichtenstein, Gary R ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Crohn's disease; Hepatic encephalopathy; Irritable bowel syndrome; Pouchitis; Rifaximin; Travelers' diarrhea

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ESOMEPRAZOLE; LACTITOL; LACTULOSE; LANSOPRAZOLE; LEVOFLOXACIN; LOPERAMIDE; MANNAN; METRONIDAZOLE; NEOMYCIN; OMEPRAZOLE; PAROMOMYCIN; PLACEBO; RIFAXIMIN; VANCOMYCIN;

BACTERIAL GROWTH; CAMPYLOBACTER; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COCCIDIA; COLITIS; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE ASSOCIATION; DIVERTICULOSIS; DRUG DOSE INCREASE; DRUG EFFICACY; ENTERITIS; ESCHERICHIA COLI; HELICOBACTER PYLORI; HEPATIC ENCEPHALOPATHY; HUMAN; ILEITIS; IRRITABLE COLON; META ANALYSIS; MONOTHERAPY; NAUSEA AND VOMITING; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; SALMONELLA; SHIGELLA FLEXNERI; SYSTEMATIC REVIEW; TRAVELLER DIARRHEA; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 34347393443     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord. 2005;5:19-30.
2. Adachi JA, DuPont HL. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis. 2006;42:541-547.
3. Su CG, Aberra F, Lichtenstein GR. Utility of the nonabsorbed (<0.4%) antibiotic rifaximin in gastroenterology and hepatology. Gastroenterol Hepatol. 2006;2:186-197.
4. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion. 2006;73(suppl 1): 13-27.
5. Koo HL, DuPont HL. Current and future developments in travelers' diarrhea therapy. Expert Rev Anti Infect Ther. 2006;4:417-427.
6. DuPont HL, Ericsson CD, Mathewson JJ, et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion. 1998;59:708-714.
7. Steffen R, Sack DA, Riopel L, et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol. 2003;98:1073-1078.
8. DuPont HL, Jiang Z-D, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33:1807-1815.
9. Taylor DN, Bourgeois AL, Ericsson CD, et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg. 2006;74:1060-1066.
10. DuPont HL, Jiang Z-D, Belkind-Gerson J, et al. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol. 2007;5:451-456.
11. Castelli F, Pezzoli C, Tomasoni L. Epidemiology of travelers' diarrhea. J Travel Med. 2001;8(suppl 2):S26-S30.
12. DuPont HL, Haake R, Taylor DN, et al. Rifaximin trearment of pathogennegative travelers' diarrhea. J Travel Med. 2007;14:16-19.
13. DuPont HL, Jiang Z-D, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med. 2005;142:805-812.
14. DuPont HL, Ericsson CD, de la Cabada FJ, et al. Prevention of travelers' diarrhea with rifaximin - a phase 3 randomized double-blind placebo-controlled trial in U.S. students in Mexico [abstract]. Am J Gastroenterol. 2006;101(suppl): S197-S198.
15. Taylor DN, McKenzie R, Durbin A, et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis. 2006;42:1283-1288.
16. Marchese A, Salerno A, Pesce A, et al. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy. 2000; 46:253-266.
17. Gerding DN, Johnson S, Osmolski JR, et al. In vitro activity of ramoplanin, rifalazil, rifaximin, metronidazole, and vancomycin against 110 unique toxigenic Clostridium difficile clinical isolates [abstract]. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. December 16-19, 2005; Washington, DC.
18. Kokkotou E, Mustafa N, O'Brien M, et al. Rifaximin: a novel non-absorbed antibiotic therapy for Clostridium difficile associated diarrhea (CDAD) [abstract]. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. December 36-19, 2005, Washington, DC.
19. Boero M, Berti E, Morgando A, Verme G. Treatment for colitis caused by Clostridium difficile: results of a randomized open study of rifaximin vs. vancomycin. Microbiologia Medica. 1990;5:74-77.
20. Berenbaum PL. Oral rifaximin in treatment of Clostridium difficile-associated diarrhea [abstract]. Am J Gastroenterol. 2006;101(suppl):S199-S200.
21. Rubin DT, Sohi S, Glathar M, et al. Rifaximin is effective and safe for the treatment of Clostridium difficile-associated diarrhea [abstract]. Am J Gastroenterol. 2006;101(suppl):S208.
22. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-asociated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44:846-848.
23. Dillingham RA, Lima AA, Guerrant RL. Cryptosporidiosis: epidemiology and impact. Microbes Infect. 2002;4:1059-1066.
24. Amenta M, Dalle Nogare ER, Colomba C, et al. Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blatocystis hominis infections. J Chemotherapy. 1999;11:391-395.
25. Gathe JC Jr, Smith K, Mayberry C, et al. Cure of severe cryptosporidial diarrhea with rifaximin in patients with AIDS [abstract]. Presented at the 10th European AIDS Conference/European AIDS Clinical Society (EACS). November 17-20, 2005; Dublin, Ireland.
26. Holton J, Vaira D, Menegatti M, Barbara L. The susceptibility of Helicobacter pylori to the rifamycin, rifaximin. J Antimicrob Chemother. 1995;35:545-549.
27. Gasbarrini A, Gasbarrini G, Pelosini I, Scarpignato C. Eradication of Helicobacter pylori: are rifaximin-based regimens effective? Digestion. 2006;73(suppl 1):129-135.
28. Hilal RE, Hilal T. The efficacy and tolerability of rifaximin, doxycycline and lansoprazole in the treatment of H. pylori gastritis: an open label pilot study [abstract]. Am J Gastroenterol. 2005;100(suppl):S57.
29. Basu PP, Palumbo FM, Maltby M, et al. Rifaximin, omeprazole and levofloxacin for the treatment of Helicobacter pylori in the treatment-naive population [abstract]. Am J Gastroenterol. 2006;101(suppl):S90-S91.
30. Gasbarrini A, Lauritano EC, Nista EC, et al. Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. Dig Dis. 2006;24:195-200.
31. Gionchetti P, Rizzello F, Lammers KM, et al. Antimicrobials in the management of inflammatory bowel disease. Digestion. 2006;73(suppl 1):77-85.
32. Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Curr Med Res Opin. 2005;21:1165-1169.
33. Bosworth BP, Scherl EJ. A novel nonabsorbable antibiotic (rifaximin) in the treatment of moderate to severe Crohn's disease [abstract]. Gastroenterology. 2005;128(4 suppl 2):A-576.
34. Pinto A, Borruto G, Dell'Anna A, et al. An open, uncontrolled trial of oral rifaximin, a non-absorbable antibiotic, in inflammatory bowel disease refractory to conventional therapy. Eur J Clin Res. 1997;9:217-224.
35. Guslandi M, Giollo P, Testoni PA. Corticosteroid-sparing effect of rifaximin, a nonabsorbable oral antibiotic, in active ulcerative colitis: preliminary clinical experience. Curr Ther Res. 2004;65:292-296.
36. Blonski W, Kundu R, Lichtenstein GR. Efficacy of rifaximin in steroid dependent Crohn's disease [abstract]. Am J Gastroenterol. 2005;100(suppl):S241-S242.
37. Finkelstein W. Rifaximin in the treatment of refractory Crohn's disease [abstract]. Am J Gastroenterol. 2006;101 (suppl):S226.
38. Doman DB, Goldberg HJ, Golding MI. Rifaximin antibiotic therapy followed by Flora-Q probiotic therapy for patients with flares of Crohn's disease despite 6-mercaptopurine maintenance therapy: a case series of "ecologic niche" therapy [abstract]. Am J Gastroenterol. 2006;101(suppl):S256- S257,
39. Shafran I. Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity [abstract]. Am J Gastroenterol. 2006;101(suppl):S429.
40. Shafran I. Is monotherapy with an oral antibiotic useful in reducing Crohn's disease activity? [abstract]. Am J Gastroenterol. 2006;101(suppl):S264.
41. Kornbluth A, Hunt M, George J, et al. Efficacy and safety of open label rifaximin in the treatment of mild-moderate Crohn's disease (CD) refractory to multiple therapies [abstract]. Am J Gastroenterol. 2006;101(suppl):S449.
42. Baidoo L, Blonski W, Kundu R, Lichtenstein GR. Rifaximin for mild to moderately active Crohn's disease [abstract]. Am J Gastroenterol. 2005;100(suppl): S319-S320.
43. Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther. 2006;23:1117-1125.
44. Pardi DS, Sandborn WJ. Systematic review: the management of pouchitis. Aliment Pharmacol Ther. 2006;23:1087-1096.
45. Baidoo L, Kundu R, Su C, et al. Rifaximin is an effective antibiotic for the treatment of pouchitis [abstract]. Gastroenterology. 2005;128(4 suppl 2):A797.
46. Kornbluth A, Hunt M, George J, Legnani P. An open label pilot trial of rifaximin in the treatment of patients with refractory pouchitis [abstract]. Gastroenterology. 2006;130(4 suppl 2):A658.
47. Shen B, Fazio V, Remzi F, et al. Oral rifaximin as maintenance therapy for antibiotic-dependent pouchitis [abstract]. Am J Gastroenterol. 2006;101 (suppl): S441-S442.
48. Colecchia A, Sandri L, Capodicasa S, et al. Diverticular disease of the colon: new perspectives in symptom development and treatment. World J Gastroenterol. 2003;9:1385-1389.
49. Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Ital J Gastroenterol. 1992;24:452-456.
50. Latella G, Pimpo MT, Sottili S, et al. Rifaximin improves symproms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis. 2003;18:55-62.
51. Colecchia A, Vestito A, Pasqui F, et al. Efficacy of long term cyclic administration of the poorly absorbed antibiotic rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol. 2007;13:264-269.
52. D'Inca R, Pomerri F, Vettorato MG, et al. Interaction between rifaximin and dietary fibre in patients with diverticular disease. Aliment Pharmacol Ther. 2007;25:771-779.
53. Williams R, Bass N. Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety. Rev Gastroenterol Disord. 2005;5(suppl 1):S10-S18.
54. United States Food and Drug Administration. Cumulative list of all orphan designated products. Available at: www.fda.gov/orphan/designat/alldes.rtf. Accessed March 5, 2007.
55. Paik Y-H, Lee KS, Han K-H, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J. 2005;46:399-407.
56. Bass N, Haake R, Gilbert SA, Kesler KL. A meta-analysis of rifaximin for the treatment of hepatic encephalopathy [abstract], Hepatology. 2005;42 (suppl 1):406A.
57. Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci. 2007;52: 737-741.
58. Neff GW, Kemmer N, Zacharias VC, et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc. 2006;38:3552-3555.
59. Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005;42:674-679.
60. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA. 2004;292:852-858.
61. Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in parients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326-333.
62. Baidoo L, Kundu R, Berenbaum PL, et al. Rifaximin is effective therapy for small bowel bacterial overgrowth [abstract]. Gastroenterology. 2005;128(4 suppl 2):A-672.
63. Di Stefano M, Malservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2000;14:551-556.
64. Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol. 2006;52:89-95.
65. Lee H-R, Low K, Chatterjee S, et al. In the treatment of IBS, the clinical response to rifaximin is determined by the normalization of the lactulose breath test [abstract]. Am J Gastroenterol. 2006;101(suppl):S474-S475.
66. Majewski M, Sostarich S, Foran P, McCallum RW. Is rifaximin effective treatment for small intestinal bacterial overgrowth? [abstract]. Am J Gastroenterol. 2006;101(suppl):S141.
67. George J, Hunt M, Kornbluth A, Legnani P. An open label pilot trial of high dose rifaximin in the treatment of patients with constipation predominant irritable bowel syndrome [abstract]. Gastroenterology. 2006;130(4 suppl 2):A515.
68. Weinstock LB, Todorczuk JR, Fern SE, Thyssen EP. Comprehensive small intestinal bacterial overgrowth (SIBO) therapy for irritable bowel syndrome (IBS) [abstract]. Am J Gastroenterol. 2006;101 (suppl):S470-S471.
69. Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;22:31-35.
70. Lauritano EC, Lupascu A, Scarpellini E, et al. A dose-finding study of rifaximin in the treatment of small bowel bacterial overgrowth in patients with irritable bowel syndrome [abstract]. Gastroenterology. 2006;130(4 suppl 2):A317.
71. Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2007;25:781-786.
72. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145:557-563.